Evident Identifies Ovarian Cancer With Proprietary
EV Testing Technology
Evident analyzes unique surface biomarkers for ovarian cancer on extracellular vesicles (or EVs)
EVs are tiny “signal carriers” in the blood. They are highly abundant—even in early-stage cancer—so only a small blood sample is needed.
This cutting-edge approach provides greater sensitivity in detecting early-stage disease compared to other technologies. A simple blood draw provides a binary result—signal detected or signal not detected—making the test straightforward, reliable, and clinically accurate.
EVs are abundant, tumor-specific, and stable
Clear results can be delivered quickly
Testing only requires small blood samples
Integrates easily into routine care
A Deeper Dive Into the Science of Early Cancer
Detection
Evident analyzes tumor-associated EVs using immunoaffinity capture and multiplex proximity-ligation PCR. This enables detection of multiple biomarker signatures colocalized within the same EV—improving both sensitivity and specificity relative to serum analytes.
